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1  | BACKGROUND
In	 2012,	 the	 International	 Federation	 of	 Obstetrics	 and	
Gynecology	(FIGO)	produced	a	chart	detailing	recommended	dos-
ages	of	misoprostol	when	used	alone,	for	a	variety	of	gynecologic	
and	obstetric	indications.	In	light	of	new	evidence1–13	and	through	
expert	deliberation,	this	chart	has	now	been	revised	and	expanded	
(Fig.	1).	Some	areas	were	particularly	challenging	to	develop	given	
the	 limited,	 low-	quality,	 or	 inconsistent	 evidence.	 The	 present	
commentary	is	intended	to	explain	some	of	the	changes	and	deci-
sions	made.
2  | GENERAL CHANGES
The	layout	is	now	categorized	vertically	by	gestation	and	horizontally	
by	 indication.	Gestation	 is	 labelled	and	referred	to	as	the	number	of	
weeks	of	gestation	 (<13	weeks,	13–26	weeks,	 and	>26	weeks),	with	
the	final	 column	being	 for	postpartum	use.	However,	 in	 the	 case	of	
incomplete	abortion	under	13	weeks,	and	inevitable	abortion	between	
13–26	weeks,	women	should	be	treated	on	the	basis	of	their	uterine	
size	rather	than	last	menstrual	period	dating.	Recommendations	have	
been	added	for	inevitable	abortion	and	cervical	preparation	between	
13	 and	 26	weeks,	 and	 for	 termination	 of	 pregnancy	 at	 more	 than	
26	weeks.
3  | NUMBER OF DOSES
For	less	than	13	weeks’	gestation,	we	decided	to	recommend	a	fixed	
number	of	doses	without	specifying	a	maximum.	This	is	because	many	
early	pregnancy	regimens	will	be	used	on	an	outpatient	basis,	so	it	is	
useful	for	healthcare	providers	to	know	in	advance	how	many	doses	
to	give	the	client;	there	is	also	sufficient	evidence	to	support	a	fixed	
number	of	doses	for	use	in	pregnancies	of	less	than	13	weeks’	gesta-
tion,	as	well	as	evidence	that	it	is	safe	to	give	further	doses	if	they	are	
required.1–4,14
For	13–26	weeks’	gestation,	the	notion	of	a	maximum	number	of	
doses	has	been	extrapolated	from	clinical	research	in	which	maximum	
doses	are	commonly	noted	not	on	the	basis	of	patient	safety	issues	or	
efficacy,9	but	rather	as	tangible	endpoints.	In	clinical	practice,	however,	
they	 might	 not	 have	 great	 utility,	 and	 dosing	 should	 continue	 until	
expulsion,	in	the	absence	of	rare	complications.	Suggesting	that	provid-
ers	should	discontinue	dosing	could	actually	increase	risks,	particularly	
when	providers	have	few	alternatives	available	if	expulsion	has	not	yet	
occurred.	Some	unpublished	studies	and	clinical	experience	have	shown	
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that	complete	expulsion	can	be	safely	achieved	by	continuing	the	regi-
men	up	to	72	hours,	without	compromising	the	woman’s	safety.9
4  | ROUTE OF ADMINISTRATION
Given	 recently	 published	 evidence,2–9	 we	 have	 added	 alternative	
routes	 for	 taking	 misoprostol;	 in	 most	 cases,	 this	 has	 meant	 the	
addition	of	the	buccal	route,	in	which	the	tablets	are	placed	in	the	
cheek	for	30	minutes	after	which	any	remnants	are	swallowed.	This	
route	 has	 a	 similar	 pharmacokinetic	 profile	 to	 the	 vaginal	 route.	
Further	ongoing	studies	are	indicating	this	to	be	a	promising	route	
for	other	 indications	on	 the	 chart,	 but	 these	 indications	have	not	
been	 included	 because	 data	 on	 efficacy	 have	 not	 been	 reported.	
Future	 studies	 will	 continue	 to	 provide	 evidence	 on	 what	 might	
be	 a	 variety	 of	 effective	 regimens	 and	 routes	 of	 administration.	
Although	this	could	result	in	several	available	options	for	providers,	
it	 will	 also	 enable	 women’s	 preferences	 to	 be	 taken	 into	 consid-
eration.	Women’s	preferences	 can	vary,	with	 some	preferring	 the	
vaginal	route	(if	inserting	the	pills	themselves)	and	some	preferring	
non-	vaginal	routes.	However,	the	vaginal	route	should	be	avoided	
when	there	is	bleeding	and/or	signs	of	infection.	The	chart	does	not	
include	 the	 rectal	 route.	We	 recommend	 against	 using	 this	 route	
because	the	pharmacokinetic	profile	is	not	associated	with	the	best	
efficacy.
5  | MISOPROSTOL USE IN PREGNANCIES 
WITH PREVIOUS CESAREAN OR 
TRANSMURAL UTERINE SCAR
The	 use	 of	 misoprostol	 at	 13–26	weeks’	 gestation	 in	 women	 with	
previous	cesarean	or	transmural	uterine	scar	was	debated	because	of	
concerns	about	an	 increased	risk	of	uterine	rupture.	For	fetal	death,	
a	Cochrane	meta-	analysis15	reported	mixed	findings,	concluding	that	
the	data	were	insufficient	to	assess	the	occurrence	of	uterine	rupture.	
A	few	studies	have	reported	no	increased	likelihood	of	rupture,16 but 
often	women	with	prior	cesarean	or	uterine	surgery	are	excluded	from	
studies	or	reviews,	or	trials	are	insufficiently	powered	to	detect	a	dif-
ference	in	safety	outcomes	as	a	result	of	the	rarity	of	major	adverse	
events.	There	is	some	evidence	that,	for	terminations	in	this	period,	the	
risk	of	uterine	rupture	among	women	with	a	prior	cesarean	delivery	
using	misoprostol	is	less	than	0.3%1,17;	other	studies9,18–20	concluded	
that	there	are	no	significant	differences	in	outcomes	for	women	with	
previous	cesarean(s).	We	therefore	concluded	that	misoprostol	can	be	
used	for	women	with	previous	cesarean	or	other	transmural	uterine	
scar	throughout	13–26	weeks.
There	is	insufficient	evidence	available	to	recommend	a	regimen	
of	misoprostol	for	use	at	more	than	26	weeks’	gestation	in	women	
who	 have	 had	 a	 previous	 cesarean	 or	 transmural	 uterine	 scar.	
Therefore,	without	evidence	to	support	a	safe	regimen,	we	do	not	
provide	 one,	 other	 than	 to	 recommend	 following	 local	 protocol	 in	
these	cases.
6  | MANAGEMENT OF PREGNANCY 
TERMINATION AND FETAL DEATH OVER 
26 WEEKS’ GESTATION
Although	there	 is	some	evidence	to	support	a	decreasing	dose	with	
increasing	gestational	age,	there	is	little	evidence	to	support	the	advice	
given	 in	 some	 international	 and	 national	 clinical	 guidelines	 to	 use	
lower	doses	of	misoprostol	in	cases	of	fetal	death.	Irrespective	of	the	
issue	of	recommendations	for	different	doses,	various	reviews15,20,21 
have	concluded	that	there	is	insufficient	evidence	overall	of	superior-
ity	 of	 one	dose	or	 schedule	 of	misoprostol	 over	 another	 for	 use	 in	
pregnancies	 at	 or	 over	 13	weeks’	 gestation.	 In	 making	 recommen-
dations,	we	acknowledged	 that	providers	might	be	keen	 to	 identify	
lowest	possible	doses	because	of	reduced	adverse	effects,21	but	that	
it	was	also	important	to	consider	success	rates	and	time	to	delivery:	
low	doses	have	been	shown	to	be	associated	with	a	longer	induction-	
to-	delivery	 interval	 and	 lower	 overall	 effectiveness,15,21	 and	 evi-
dence	has	supported	the	safety	of	the	“higher”	doses	for	women.7–9 
Recommendations	in	the	chart	were	compiled	with	this	in	mind,	while	
also	acknowledging	that	it	is	possible	that	a	range	of	dosages	could	be	
effective	and	safe.
7  | RETAINED PLACENTA
There	have	been	two	studies	of	the	use	of	misoprostol	for	the	treat-
ment	of	retained	placenta	following	live	birth,	neither	of	which	show	
any	 benefit	 over	 placebo.22	We	 therefore	 do	 not	 recommend	mis-
oprostol	for	retained	placenta	in	late	pregnancy.
8  | SECONDARY PREVENTION OF 
POSTPARTUM HEMORRHAGE FOR 
COMMUNITY- BASED PROGRAMS
Secondary	prevention	 is	a	community-	based	strategy	 that	has	been	
shown	 to	 be	 a	 comparable	 alternative	 to	 a	 universal	 prophylaxis	
approach	in	two	large	community	trials	(one	in	press).12	Rather	than	
medicating	all	women	during	the	third	stage	of	labor	with	a	prophy-
lactic	dose,	a	regimen	of	800	μg	sublingual	misoprostol	(the	same	as	
for	 treatment)	 can	 be	 used	 to	 treat	 only	women	with	 higher-	than-	
average	bleeding	(e.g.	approximately	350	mL	or	more).	Although	there	
is		limited	published	data,	it	was	agreed	that	secondary	prevention	of	
PPH	is	a	strong	alternative	approach	to	universal	prophylaxis,	because	
it	 involves	 medicating	 far	 fewer	 women	 (5%–10%	 vs	 100%),	 thus	
causing	fewer	adverse	effects	and	reducing	costs.
9  | CONCLUSION
The	 FIGO	 Misoprostol-only Recommended Regimens 2017	 chart	
(Fig.	1)	is	the	result	of	extensive	collaboration	among	an	international	
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expert	 group.	 It	 has	 been	 endorsed	 by	 the	 FIGO	 Prevention	 of	
Unsafe	 Abortion	Working	 Group	 and	 the	 FIGO	 Safe	Motherhood	
and	Newborn	Health	Committee,	and	approved	by	the	FIGO	Officers.	
Available	 in	 other	 languages	 and	 formats	 from	http://figo.org,	 it	 is	
hoped	that	it	will	be	as	widely	distributed	and	used	as	the	previous	
version.	Although	 these	 recommended	dosages	have	been	decided	
on	the	basis	of	current	evidence	available	and	expert	opinion,	new	
evidence	is	regularly	emerging	and	thus	there	is	a	need	to	review	and	
revise	these	recommendations	in	the	future.
Misoprostol	is	an	important	medicine	and,	although	it	should	not	
be	 used	 in	 preference	 over	 oxytocin	 for	 postpartum	 hemorrhage,	
or	 instead	 of	 mifepristone	 plus	misoprostol	 for	 pregnancy	 termina-
tion,	 it	 could	be	 the	only	medicine	available	 in	some	circumstances,	
which	 is	why	FIGO	believes	this	 “misoprostol-	only”	chart	 is	needed.	
Misoprostol	must	continue	to	be	highlighted	as	an	essential	medicine	
and	 included	 in	 international	 documents,	 national	 guidelines,	 and	
essential	medicines	 lists.	Further,	we	must	work	to	ensure	the	avail-
ability	of	high-	quality	misoprostol,	and	the	establishment	of	policy	and	
programs	that	support	its	availability	and	use.
The	 recent	WHO	guidelines	on	health	worker	 roles	 in	providing	
safe	abortion	care23	outline	a	wide	variety	of	healthcare	providers	who	
can	manage	medical	 abortion	 and	postabortion	 care	 in	 the	first	 tri-
mester,	with	auxiliary	nurses,	nurses,	and	midwives	 listed,	as	well	as	
lay	health	workers	and	doctors	of	complementary	systems	for	some	
subtasks.	Women	can	also	fulfill	some	of	the	components	of	assess-
ment	and	management	themselves	outside	of	a	healthcare	facility.	It	
is	anticipated	that	this	misoprostol	chart	can	be	used	by	all	healthcare	
providers	identified	in	the	WHO	publication	and	that	by	implementing	
both,	we	will	come	closer	to	achieving	optimal	care	for	the	women	we	
aim	to	serve.
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